go-v.orgdoi

Role of anti-EGFR target therapy in colorectal carcinoma

Aranda-Aguilar Enrique · Frontiers in Bioscience-Elite · 2011

  • DOI 10.2741/357
  • Publisher Frontiers Media
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Frontiers in Bioscience-Elite · Frontiers Media · article · 2011

Abstract

The epidermal growth factor receptor (EGFR) has become an important target in cancer treatment. In consequence, drugs directed at this and other molecular targets are an increasingly important part of the treatment of numerous tumours. Cetuximab and panitumumab, two monoclonal antibodies that target EGFR, have proved to be effective in metastatic colorectal cancer treatment. However, some patients do not respond to treatment with EGFR inhibitors and, for this reason, interest in the identification of patients most likely to benefit from treatment with these agents has grown considerably.

K-Ras, a member of the RAS family of signalling proteins plays an important role in EGFR- mediated regulation of cellular proliferation and survival. Patients with wild-type K-Ras were found to have significantly greater overall survival, progression-free survival and/or response rate compared with patients harbouring K-Ras mutations.

Open the resolved locator · 10.2741/357

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 15:54 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.imrpress.com/journal/FBE/4/1/10.2741/e357
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.